A Review of the Use of Iloprost, A Synthetic Prostacyclin, in the Prevention of Radiocontrast Nephropathy in Patients Undergoing Coronary Angiography and Intervention. Issue 8 (12th May 2015)

• Record Type: Journal Article
• Authors: Kassis, Hayah M.; Minsinger, Kristopher D.; McCullough, Peter A.; Block, Clay A.; Sidhu, Mandeep S.; Brown, Jeremiah R.
• Is Part Of: Clinical cardiology. Volume 38:Issue 8(2015:Aug.)
• Page Start: 492
• Page End: 498
• Publication Date: 2015-05-12
• Subjects: Cardiology -- Periodicals; 616.12005
• DOI: 10.1002/clc.22407
• Languages: English
• ISSNs: 0160-9289

Abstract

<abstract abstract-type="main" id="clc22407-abs-0001"> <title>ABSTRACT</title> <p id="clc22407-para-0001">Iloprost, a prostacyclin analogue, has been effective in preventing renal dysfunction among transplant patients. We hypothesized that iloprost is protective against renal dysfunction in different settings, in which similar underlying mechanisms of nephrotoxicity occur. We conducted a literature review, and discuss the application of iloprost in reducing acute renal insufficiency and the pathophysiological mechanisms of contrast‐induced nephropathy (CIN). One proposed mechanism of CIN is prolonged renal arterial vasoconstriction, causing renal hypoperfusion, ischemia, and release of free radicals. Iloprost is an analogue of the vasodilatory prostaglandin PGI<sub>2</sub>. It has demonstrated cytoprotective properties in the renal transplant population by inhibiting lysosomal degradation and release of free radicals, allowing membrane stabilization. Two good‐quality studies reported on iloprost and CIN. Five studies reported protective effects of iloprost in renal transplantation and 1 in coronary artery bypass grafting. Iloprost was found to be renoprotective in patients with baseline renal insufficiency who underwent coronary angiography for CIN (risk ratio [RR] = 0.32, 95% confidence interval [CI]: 0.16‐0.67) and increases the weighted mean difference improvement in creatinine clearance (RR = 4.56, 95% CI: 1.82‐7.30). CIN is associated with major adverse cardiac events. Preventing CIN is important for patient safety and reducing disease burden. Iloprost may reduce CIN by up to 68%. The same mechanisms of iloprost that inhibit graft dysfunction in the acute post–renal transplant and cardiopulmonary bypass setting may also contribute to preventing CIN. Large randomized controlled trials are necessary to determine the clinical efficacy of iloprost in the angiography setting.</p> </abstract>